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Abstract
Although the technique of intracytoplasmic sperm injection (ICSI) has been a revolution in the alleviation of male
infertility, the use of testicular sperm for ICSI was a formerly unseen breakthrough in the treatment of the azoospermic
man with primary testicular failure. At the clinical level, different procedures of testicular sperm retrieval (conventional
TESE, micro-TESE, FNA/TESA, MESA, PESA) are being performed, the choice is mainly based on the cause of azoospermia
(obstructive versus non-obstructive) and the surgeon’s skills. At the level of the IVF laboratory, mechanical procedures to
harvest the sperm from the tissue may be combined with enzymatic treatment in order to increase the sperm recovery
rates. A number of techniques have been developed for viable sperm selection in males with only immotile testicular
sperm available. However, large, well-designed studies on the benefit and safety of one over the other technique are
lacking. Despite all the available methods and combinations of laboratory procedures which have a common goal to
maximize sperm recovery from testicular samples, a large proportion of NOA patients fail to father a genetically own
child. Advanced technology application may improve recovery rates by detection of the testicular foci with active
spermatogenesis and/or identification of the rare individual sperm in the testicular suspensions. On the other hand, in
vitro spermatogenesis or sperm production from embryonic stem cells or induced pluripotent stem cells might be
future options. The present review summarizes the available strategies which aim to maximize sperm recovery from
surgically retrieved samples.
Keywords: Testicular, Epididymal, Obstructive azoospermia, Non-obstructive azoospermia sperm motility, Sperm
morphology, Sperm selection, ICSI
Résumé
Bien que la technique d’injection intra cytoplasmique d’un spermatozoïde (ICSI) ait constitué une révolution dans le
soulagement de l’infertilité masculine, l’utilisation de spermatozoïdes testiculaires lors de l’ICSI fut une découverte
capitale auparavant inaperçue du traitement de l’homme azoospermique par altération testiculaire primaire. Au plan
clinique, différentes procédures de recueil des spermatozoïdes testiculaires sont réalisées (TESE conventionnelle,
micro-TESE, FNA/TESA, MESA, PESA) dont le choix dépend principalement de la cause de l’azoospermie (obstructive
versus non obstructive) et des compétences du chirurgien. Au plan du laboratoire de fécondation in vitro, des
procédures mécaniques d’extraction des spermatozoïdes du tissu peuvent être combinées avec un traitement
enzymatique dans l’objectif d’accroitre le taux de récupération de spermatozoïdes. Plusieurs techniques ont été
développées pour sélectionner des spermatozoïdes vivants chez les hommes n’ayant que des spermatozoïdes
testiculaires immobiles. Toutefois, il manque des études bien construites et à effectifs consistants portant sur le
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bénéfice et l’innocuité d’une technique par rapport aux autres. Malgré toutes les méthodes et combinaisons de
procédures de laboratoire disponibles qui ont comme objectif commun d’accroitre au maximum la récupération
de spermatozoïdes dans les échantillons testiculaires, un grand nombre de patients avec NOA échouent à obtenir
un enfant qui soit génétiquement leur. L’utilisation d’une technologie de pointe devrait améliorer les taux de
récupération par la détection de foyers testiculaires ayant une spermatogenèse active et/ou l’identification de rare
spermatozoïde isolé dans les suspensions testiculaires. D’autre part, la spermatogenèse in vitro ou la production de
spermatozoïdes à partir de cellules souches embryonnaires ou de cellules souches pluripotentes induites pourraient
constituer de futures options. Le présent article de revue résume les stratégies disponibles qui visent à maximiser la
récupération de spermatozoïdes dans des échantillons extraits chirurgicalement.
Mots clés: Testiculaire, Epididymaire, Azoospermie obstructive, Azoospermie non obstructive, Mobilité spermatozoïdaire,
Morphologie spermatozoïdaire, Sélection des spermatozoïdes, ICSI
Background
Although the introduction of intracytoplasmic sperm in-
jection (ICSI) in 1992 was a major breakthrough in the
treatment of male infertility [1], the successful use of epi-
didymal and testicular sperm a few years later was a
formerly unseen revolution in the treatment of the azoo-
spermic man [2–4].
Azoospermia, defined as the absence of spermatozoa
in the ejaculate after assessment of centrifuged semen
on at least two occasions, is observed in 1% of the general
population and in 10–15% of infertile men [5]. It can be
clinically classified as either obstructive (OA, 40%) or
non-obstructive azoospermia (NOA, 60%). Sperm retrieval
is nearly 100% successful in OA patients, but the prob-
ability of finding sperm is around 50% in an unselected
population of NOA patients [6]. While in OA a lot of
sperm can be retrieved with epididymal aspirations
(MESA, PESA), multiple testicular biopsies (TESE or
micro-TESE) is the retrieval procedure of choice in
NOA patients [7]. A Cochrane meta-analysis on surgi-
cal sperm retrieval techniques concluded that there is
insufficient evidence to recommend any specific tech-
nique and that the least invasive technique should be
used [8]. More recent reviews which focus on only NOA
concluded that microsurgical TESE may be associated with
a higher recovery rate. However, this conclusion should be
interpreted witch caution due to the inclusion of low
quality cohort studies [9, 10]. ART success rates after ICSI
with testicular sperm may highly vary according to the
cause of azoospermia and the selection of the patients.
Overall, non-obstructive azoospermia results in both
lower fertilization and clinical pregnancy rates than ob-
structive azoospermia [11]. Additionally in NOA, the ART
laboratory is challenged to efficiently process the tissue
and to select those sperm with the highest potential to
fertilize the oocyte and produce a competent embryo. The
present review summarizes the evolution in the processing
and selection of surgically retrieved sperm.
Methods
An extensive computer search of PUBMED was per-
formed using combinations of mainly the following
search terms: “testicular sperm”, “epididymal sperm”,
“non-obstructive azoospermia”, “obstructive azoosper-
mia”, “immotile sperm,” “sperm selection”, “DNA frag-
mentation”, “mechanical”, “enzymatic”, “pentoxifylline”,
“biregringence”. Reference lists of relevant articles and
reviews were also analyzed for further articles. After re-
view of titles and abstracts, references were limited to
the original paper(s) describing the technique for the
first time and/or to the more important papers related
to the topic. A list of relevant articles that discussed
laboratory techniques which are used to process and se-
lect sperm in the testicular samples as well as the future
aspects was compiled and included in the review.
Where do we come from?
Epididymal sperm
In 1994 [3], Tournaye et al. reported successful fertilization
and pregnancy rates with sperm obtained by microsurgical
epididymal sperm aspiration (MESA) in patients with con-
genital bilateral absence of the vas deferens (CBAVD).
MESA allows large sperm numbers with minimal contami-
nation of red blood cells and non-germ cells to be re-
trieved. The aspirates are then simply emptied in a tube
containing a buffered medium, and after mixing, a droplet
is used to assess the quality of the spermatozoa (density,
motility and estimation of morphology). If low numbers
are obtained, the sample can be treated by double washing
and centrifugation. In case of high numbers, density
gradient centrifugation (90–45% or 80–40%) followed by
double washing is preferred for selection of a motile frac-
tion with better morphology. Ten μl droplets of the final
sperm fraction are smeared on the bottom of a Petri
dish and overlaid with oil. Motile sperm with good
morphology are aspirated directly from this dish,
immobilized and injected into the oocyte. In most
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cases, supernumerary sperm, left in the tube, can be fro-
zen and successfully used in subsequent ICSI cycles [12].
Although high sperm numbers can be retrieved with
MESA in almost all patients with obstructive azoospermia,
ICSI technique is more successful than conventional IVF
both in terms of fertilization and pregnancy rates [13].
Shortly after the introduction of MESA, percutaneous
epididymal sperm aspiration (PESA) has been described
as effective, simpler, and less traumatic alternative to
MESA for patients with obstructive azoospermia [14, 15].
Nowadays, some units replaced the MESA procedure by
PESA or testicular sperm retrieval. If performed by an ex-
perienced clinician, equally high sperm numbers may be
obtained with PESA and MESA, and the processing of the
obtained samples is similar.
Testicular sperm
In the early nineties, the fertilizing capacity of human
sperm directly retrieved from the testis has been discovered
[2, 16]. Since then, the use of testicular sperm has become
a routine procedure to circumvent infertility in patients
with OA. A few years later this approach was also used to
yield sperm in NOA patients [4, 17]. Although sperm re-
trieval and the outcome of ICSI are highly successful in OA
patients, it remains a challenge in NOA patients, both
at the clinical and the laboratory level. Notwithstanding
several clinical characteristics (histopathology, FSH,
Inhibin B) have been suggested, no single pre-operative
parameter or combinations seem to accurately predict
the ability to retrieve sperm surgically [6, 18–20]. Dif-
ferent surgical procedures are applied with different
success rates according to the etiology of azoospermia,
histological diagnosis and the surgical preference and
expertise. While open testicular biopsy retrieval (TESE)
or fine-needle aspiration (FNA/TESA) should guarantee
sperm recovery in almost 100% of OA patients, TESE
or micro-TESE [21] are the treatments of choice in
NOA patients with the sperm recovery spans up to 40–
50%, the micro-TESE potentially being 1.5 times more
successful in retrieving sperm than TESE [10]. Considering
that micro-TESE requires additional equipment and given
low quality of evidence [9], multiple conventional TESE re-
mains the most used procedure.
At the laboratory level, the embryologists are chal-
lenged to find sperm suitable for ICSI in the testicular
tissue provided by the surgeon. In case of FNA/TESA
performed in OA men, the aspirates are released in a
tube or immediately in medium droplets under oil from
which sperm are selected for ICSI. For TESE specimens,
different procedures of processing have been described.
Mechanical processing of testicular tissue
Initially, different mechanical methods have been compared
in order to maximize sperm recovery from testicular
biopsies. Verheyen et al. [22] processed testicular tissue
pieces by rough shredding, fine mincing, vortexing and
crushing in a grinder with pestle. Fine mincing was the
most effective method regarding the total number of motile
sperm and normal morphology. Shredding and fine min-
cing of the tissue with rupture of the seminiferous tubules
is so far the preferred and most widely used tissue
processing procedure immediately after retrieval.
The excised testicular tissue is placed in a dish with
buffered medium and shredded/minced with needles,
microscope slides or scissors, by which sperm are re-
leased into the medium. The suspension is directly
assessed under the inverted microscope at 200x or 400x
magnification, or a drop is placed in a counting chamber
and assessed with a phase-contrast microscope at 200x
magnification. If sperm are easily identified, the suspen-
sion is transferred to a tube. After sedimentation of the
remaining tissue pieces during 30–60 sec, the super-
natant containing free sperm is further processed by
centrifugation at 750xg for 5 min. Post-centrifugation,
the supernatant is removed, the pellet is resuspended
and 10 μl droplets are smeared on the bottom of a Petri
dish and overlaid with oil. From this dish, the best-
looking sperm (motility and morphology) are aspirated
for ICSI. Zohdy et al. [23] described crushing of testicu-
lar biopsies quickly frozen in liquid nitrogen as an alter-
native method to improve sperm recovery. In order to
avoid the presence of heterogeneous testicular cell types
in the final fraction for ICSI, some groups successfully
included a density gradient centrifugation step [24, 25].
In NOA patients, Kamal et al. [26] showed that in vitro
microscopic dissection of the most dilated seminiferous
tubules, if present, resulted in superior sperm recovery
rates.
Erythrocyte-lysing buffer to facilitate sperm recovery
The excised testicular tissue is often highly contami-
nated with red blood cells which may hamper good
visualization of spermatozoa in the suspension, espe-
cially if they are immotile. In order to solve this prob-
lem, the tissue suspension can be exposed to an
erythrocyte-lysing buffer (ELB) [27, 28]. After tissue
shredding, the suspension is centrifuged at 750xg for
5 min. The supernatant is aspirated and discarded, and
the pellet is resuspended in 1 to 2 ml of ELB (155 mM
NH4Cl, 10 mM KHCO3, and 2 mM ethylenediaminete-
tracetic acid EDTA; pH 7.2). The mixture is incubated at
room temperature for 5 min. Next, the tube is filled up
with buffered medium to dilute the ELB and is centri-
fuged at 750xg for 5 min. The supernatant is completely
aspirated and discarded, and the pellet is resuspended in
0.5–1 ml buffered medium. From this fraction, a dish
with 10 μl droplets under oil is prepared to perform
ICSI. This technique enhances the efficiency of sperm
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collection, reduces the duration of sperm searching and
improves the sperm selection process without negatively
affect sperm fertilization potential after ICSI [28].
Enzymatic methods to improve sperm recovery
In azoospermic men in whom sperm production is very
limited, especially in NOA patients, the combination of
the limited tissue volume that can be removed, together
with the low numbers of sperm present, renders mech-
anical extraction inadequate and the search for sperm-
atozoa very complicated and time consuming. The use
of enzymes to digest the testicular tissue that often hides
the sperm is an efficient tool to improve sperm recovery.
Both collagenase type IA and collagenase type IV have
been successfully used to digest collagen as component
of the basement membrane and extracellular matrix
[28–30]. Incubation of the pelleted testicular suspension
with collagenase IV rescued the ICSI treatment cycle in
7 out of 27 NOA men for whom no sperm was found
after mechanical shredding [28]. Since then, the pro-
cedure is routinely applied in some centers after sperm
detection failure following classical mechanical shred-
ding. The enzyme solution consists of buffered medium
with 1000 IU/ml collagenase IV, 25 μg/ml DNase and
1.6 mM CaCl2. A ready-to-use product is commercially
available (GM501 Collagenase, Gynemed). After expos-
ure of the tissue pellet at 37 °C during 1 h to 1–2 ml
collagenase solution and meanwhile regularly shaking
the tubes, the reaction is stopped by addition of 10 ml
buffered medium. The digested tissue solution is gently
centrifuged at 50xg for 5 min in order to remove residual
non-digested pieces or debris. The supernatant cell sus-
pension is washed twice with buffered medium and the re-
suspended pellet is used to prepare droplets under oil. In
case of high numbers of red blood cells, ELB treatment is
preceding the double washing step. Although not widely
spread, several centers experienced the benefit of testicu-
lar tissue digestion [28, 31, 32].
This method can be considered adequate in maximizing
sperm recovery and may increase the chance of selecting
the highest quality sperm in NOA patients. Nevertheless,
the procedure may still require several hours depending
on the number of observed sperm and the number of
oocytes to be injected. With regards to recovery rates
reported after TESE, the use or non-use of enzymatic di-
gestion may be one of the many confounding factors
explaining the reported differences.
What about immature germ cells if no sperm are
recovered?
The recovery of testicular sperm fails in at least 50% of
NOA patients in unselected cohorts. Based on experi-
ments in animal models, Edwards [33] suggested the use
of round spermatids for ICSI if the more mature stages
were not available. In 1995, the first successful births
were reported by Tesarik [34] after round spermatid injec-
tion (ROSI) from the ejaculate. Since the mid-nineties,
several IVF centers worldwide have used testicular round
spermatids for ICSI despite the lack of preclinical evidence
on safety and success. Problems of correct identification
of the round spermatid in a wet preparation [35] and
several basic concerns regarding their use for ICSI had
been raised such as DNA immaturity, genomic imprinting
problems, centrosome normality, presence of the oocyte-
activating factor.
From a clinical point-of-view, maturation arrest at the
round spermatid level is an extremely rare phenomenon,
affecting only 0.9% of NOA men [36]. Birth of fewer
than twenty children after ROSI have been reported
worldwide, most of them derived from men who showed
complete spermatogenesis, which casts doubt on the
prevalence of a target population for ICSI with imma-
ture germ cells [35]. Data on ICSI with immature germ
cells, and on in-vitro maturation of male germ cells and
their safety concerns have been recently reviewed by
Vloeberghs et al. [37].
What progress did we make?
Nowadays, mechanical methods are still routine proce-
dures used to recover sperm from testicular specimens,
while the use of enzymatic methods is not widely spread,
despite its proven effectiveness. Nevertheless, several chal-
lenges regarding the infertility treatment of men with
NOA remain. At the clinical level, diagnostic parameters/
tests which are able to fully predict testicular sperm re-
trieval are lacking. At the laboratory level, tools have been
introduced to refine sperm selection in NOA patients.
Nagy et al. [38] demonstrated that the normal fertilization
rate was significantly lower in cycles with only non-motile
testicular sperm, and the difference was more pronounced
in NOA cases than in OA cases. The causes and treatment
options for complete immotility are reviewed by Ortega
et al. [39]. Regarding testicular sperm, fertilization, preg-
nancy and implantation rates were negatively affected when
only immotile sperm were available for ICSI in NOA pa-
tients [40, 41]. A number of methods for real-time selection
of vital immotile sperm have been tested and introduced
into clinical practice.
Sperm culture
Some groups performed the surgical procedure one day
prior to the oocyte retrieval in order to allow maturation
of sperm with the goal to gain motility. They observed
improvement of the motility during in-vitro culture,
mainly in patients with OA [42, 43]. Balaban et al.
showed the effectiveness of pre-incubating testicular
sperm of 143 NOA patients in medium supplemented
with recFSH [24]. Liu et al. [44] demonstrated that
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the results of in-vitro culture are unpredictable in cases
with NOA.
In OA patients, the only effect observed was improve-
ment of the quality of motility in samples that already
showed motility shortly after tissue retrieval. Moreover,
culture for more than 48 h seemed to cause sperm age-
ing, determined by increased DNA fragmentation and
increased structural chromosomal abnormalities [45].
Mechanical touch technique (MTT)
Since the introduction of ICSI, MTT has been used to
distinguish vital from dead immotile sperm, if only im-
motile sperm were available for injection. The technique
is based on the observation that immotile vital sperm
have a flexible tail and immotile non-vital spermatozoa
have a rigid tail upon lateral touching with the micro-
injection pipette. If the tail is flexible and recovers its
original position, the spermatozoon is considered viable.
Tail rigidity and inability to recover the initial tail
position is considered a sign of non-viability. In other
words, if the head moves together with the tail, the
spermatozoon is unsuitable for ICSI. Although this tech-
nique has been applied since the early years of ICSI, it
has first been described by de Oliveira et al. in 2004 [46]
as the sperm tail flexibility test. In both fresh and frozen
TESE-ICSI cycles, they obtained similar fertilization
rates with immotile and motile testicular sperm when
applying MTT to select immotile sperm. Additionally,
there were no differences in pregnancy and delivery rates
between groups, indicating that the selection method
was effective in identifying viable yet immotile testicular
spermatozoa.
The strength MTT is that it does not change the in-
tegrity of the sperm, and no chemical substances are
used, so that spermatozoa are ready to be injected. How-
ever, the technique is not 100% accurate and requires a
certain level of expertise of the laboratory staff. More-
over, in cases with very few sperm, it may be very time-
consuming to touch them one by one.
Hypo-osmotic swelling test (HOST)
The hypo-osmotic swelling test was first developed by
Jeyendran et al. [47] to evaluate the functional integrity
of the sperm membrane. Viable sperm with a normal
membrane function exhibit tail swelling or curling due
to the influx of water when exposed to hypo-osmotic
conditions. The use of this test to distinguish between
viable and non-viable immotile ejaculated spermatozoa
for ICSI was first proposed by Desmet et al. [48]. Tsai
et al. [49] compared four hypo-osmotic solutions and
found 150 mOsm NaCl to be the optimal HOS solution.
A modified and simpler HOS test using culture medium
and deionized grade water (1:1) was introduced by
Verheyen et al. [50] who compared three different HOS
solutions. After exposure for maximum 10 s to the mix-
ture and identification of HOS-positive sperm, they can
be aspirated and placed in an isotonic medium where
sperm regain normal shape prior to injection. This
modified HOS test has also been successfully applied to
select immotile testicular sperm for ICSI. Fertilization
rates and ongoing pregnancy rates increased from 28.2
and 2.9% in the control group (non-HOS) to 43.6% and
20.5% in the HOS group [51]. The HOS test has been
described by the World Health Organization as alterna-
tive vitality test when sperm staining must be avoided
[52]. However, false positive and false negative results re-
duce the test accuracy [53]. According to Hossain et al.,
the HOS method can not be considered a fully reliable
alternative for vital staining because of spontaneously
developed tail curling in fresh (5.9%) as well as in frozen
(6.7%) sperm samples [54].
Chemical motility enhancers
Pentoxifylline (PTF) inhibits phosphodiesterase activity
and hereby increases levels of intracellular cyclic adeno-
sine monophosphate (cAMP), a molecule which plays a
role in sperm motility [55]. While Yovich et al. [56]
introduced the use of PTF in clinical ART practice,
Tasdemir and his group [57] were the first to show its
effect on immotile testicular tissue samples as well.
Because of safety concerns, the embryo toxicity of PTF
was studied in a mouse model. This research revealed
several adverse events which, however, could be avoided
by washing sperm after their exposure to PTF [58]. It
was found that addition of PTF to epididymal or testicular
sperm not only initiated motility, but allowed fertilization,
pregnancy and birth of healthy children after ICSI [59].
PTF was added to the sperm suspension in a 1:1 ratio,
with a final PTF concentration of 3.6 mM. Addition of
PTF in a lower final concentration (1.76 mM, 47 cycles) to
immotile testicular sperm suspensions also induced
motility and increased fertilization rates (66% vs 50.9%)
and the number of available embryos (4.7 vs 2.7) after
ICSI compared to control cycles (30 cycles), and preg-
nancy rate in the PTF group tended to be higher [60].
Also when frozen-thawed testicular samples were
treated with PTF, significantly higher motility was ob-
served [61]. The use of PTF for the selection of viable
non-motile testicular sperm seemed more effective than
use of the HOS test in a study by Mangoli et al. [62].
Irrespective of the heterogeneous data regarding clini-
cal outcome, the use of PTF significantly reduces the
time of sperm identification and selection.
Another member of the xanthine family, theophylline,
has more recently been evaluated in a prospective trial on
sibling oocytes and showed an immediate but short-term
effect on sperm motility [63]. A ready-to-use product is
commercially available (GM501 SpermMobil®, Gynemed).
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To a 10 μl droplet suspension smeared on the bottom of a
dish, and overlaid with oil, 3 μl SpermMobil is added. The
activating effect initiates within 10 min, and this effect
lasts for maximum 1 h. Sperm that gained motility are
aspirated and washed in sperm buffer prior to injection.
There have been concerns regarding the safety of these
chemical compounds. In clinical settings where live births
were reported following PTF or theophylline treatment,
there is no evidence of anomalies in the offspring [64, 65],
but, as always, larger follow up studies are needed.
Laser-assisted immotile sperm selection (LAISS)
Aktan et al. [66] used the laser for the identification of
viable but immotile spermatozoa. A single laser shot of
129 μJ for approximately 1.2 msec is directed to the tip
of the flagellum which causes a coiling of the tail in vital
immotile sperm. Conversely, if no tail displacement is
observed, the sperm is dead. The number of viable
sperm in a testicular sample identified by LAISS was
comparable to that of the HOS test (22.0% vs. 21.5%)
[66]. Fertilization rate improved, from 20.4% in the
control group to 45.4% in the laser selection group. Ac-
cordingly, the take home baby rate increased from 5.9 to
19.0% [66]. Increased fertilization rate after laser-assisted
selection of immotile testicular spermatozoa has been
confirmed recently by Nordhoff et al. [67]. The use of
the laser has the advantage that it does not require any
chemical compound to induce motility, and thereby may
be considered a safer approach. The main obstacle to its
widespread application remains the high cost of the
equipment needed [68].
Birefringence –polarization microscopy (BPM)
This technique, first reported by Baccetti et al. [69], is
based on the principle that viable sperm are naturally bi-
refringent, based on their head structure, and dead
sperm are not because of their different texture. Birefrin-
gence of the sperm head, as visualized with polarized
light microscopy, reflects the health status of the cell
and seems to correlate well with its viability [69]. In
cases with severe male factor infertility, selection of im-
motile birefringence-positive sperm for ICSI resulted in
higher clinical pregnancy rates (58% vs 9%) and implant-
ation rates (42% vs 12%) than control-selected immotile
sperm [70]. According to Ghosh et al., birefringence-
based selection of immotile sperm was more effective in
terms of pregnancy rate than HOS-selection (45% vs
11%) [71]. However, these conclusions are based on
small studies, and larger studies are lacking. Moreover,
the cost of the imaging equipment for BPM is high,
while cheaper and easier methods for immotile sperm
selection are available.
It can be concluded that, although several techniques
have been developed to select viable sperm in cases with
complete immotility, each has pros and cons. Large,
properly controlled studies assessing the efficacy of the
current techniques, are currently unavailable. Whatever
technique is used, the success of ICSI with immotile
sperm remains inferior to ICSI with motile sperm.
Where are we now?
Twenty years after the introduction of the use of surgi-
cally retrieved sperm for ICSI, various retrieval tech-
niques are still being performed, their choice depending
on both the centre and the clinicians’ preference, and on
the etiology of azoospermia.
While OA patients may benefit from PESA, FNA/
TESA or eventually open TESE, multiple open excisional
sampling, either by the conventional way or by using an
operation microscope (micro-TESE), is the gold standard
for NOA patients. In the latter population particularly, it
is the embryologists’ challenge to optimize processing of
the harvested tissue in order to find the rare sperm and
select the vital and best-looking ones for micro-injection.
It remains unclear what impact the laboratory phase has
on sperm recovery rates reported in the literature, but this
phase may be more important than the skills of the
surgeon performing the retrieval. Different successful
methods in order to select vital immotile sperm have been
described, and the choice made by the IVF laboratory is
guided by team expertise, grade of experience as well as
equipment cost.
A number of processing methods are combined at the
laboratory level in order to maximize sperm harvesting
as well as the possibility to cryopreserve sperm for later
use (not discussed in this paper). After initial shredding
and mincing, enzymatic digestion of the tissue can be
performed followed by a real-time sperm vitality testing
whenever appropriate. The combination of enzymatic
treatment with density gradient centrifugation and
exposure to theophylline in order to maximize sperm
retrieval has been applied by Wöber et al. [25]. A sum-
mary of procedures for processing and selection of
surgically retrieved sperm is presented in Table 1.
Although the birth of healthy children has been de-
scribed for the different strategies of (immotile) sperm
selection in NOA patients, these are mainly case reports
or small cohort studies while larger longitudinal follow-
up studies are lacking. Moreover, many aspects related
to the individual sperm selected for ICSI remain unclear.
Possible future aspects?
A number of issues regarding the use of surgically re-
trieved sperm, of NOA patients particularly, remain un-
resolved. Currently, longitudinal follow-up shows that
more than two thirds of men with non-obstructive azoo-
spermia do not realize their wish to become a biological
father [72]. The only option for these couples is the use
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of donor sperm or adoption, which, for several reasons,
may not be valid alternatives.
The question may be raised whether more sophisti-
cated techniques which can more accurately determine
focal spermatogenesis during surgery will improve this
outlook. As for the lab phase, the use of automatic non-
invasive sperm detection techniques on the harvested
specimens may in the future increase sperm recovery
rates together with a reduction in searching time. When-
ever sperm are recovered, novel methods of sperm selec-
tion may improve the outcome after ICSI. Notwithstanding
the progress made in the treatment of NOA patients,
fertilization, embryo development, implantation rate and
delivery rates are still far below those obtained with ejacu-
lated sperm. Compared to OA with normal spermatogen-
esis, testicular sperm of NOA men is characterized by
higher DNA fragmentation [73], increased aneuploidy rates
[74], defects in spermiogenesis, and these features can cur-
rently not be identified at microscopic sperm selection for
ICSI. Raman micro-spectroscopy has been suggested for in
situ visualization of damaged DNA in living human sperm
[75, 76], but this technique still requires further validation
[77]. Increased mosaicism in the developing embryos
suggests pre-implantation genetic screening (PGS) in this
patient population. However, the PGS test nowadays im-
plies biopsy of blastocyst cells, while many IVF centers
perform replacement of cleavage-stage embryos (day 2/3)
in ICSI cycles of NOA patients.
For NOA patients with unsuccessful sperm recovery,
effective therapeutic options are currently not available,
but extensive research in animal models might create fu-
ture perspectives for male fertility restoration. Particularly
for patients diagnosed with maturation arrest, in-vitro
germ cell differentiation may offer a new therapeutic
approach. Several groups study in-vitro spermatogenesis,
either starting from testicular tissue culture [78], or from
culture of isolated testicular germ cells or spermatogonial
stem cells [79]. A variety of three-dimensional culture sys-
tems aiming to resemble the testicular micro-environment
are currently tested. A promising novel option for sperm-
atogenesis in vitro is the development of artificial scaffolds
which mimic the spatial environment in the seminifer-
ous tubules [80]. Although complete in-vitro meiosis of
testicular germ cells and successful IVF after in-vitro
spermatogenesis has been achieved in mice, its transla-
tion to the human remains a challenging issue for the
time being. So far, culture conditions do not seem opti-
mal for successful maintenance and proliferation of
human spermatogonial stem cells. A recent report
reviewed the current situation regarding human in-vitro
spermatogenesis [81].
In-vitro production of sperm from embryonic stem
cells or induced pluripotent stem cells has also been a
focus of research for a number of decades. In mice, the
generation of primordial germ cell-like cells, derived
from embryonic stem cells and from induced pluripotent
stem cells, with robust capacity for spermatogenesis has
led to healthy offspring which developed normally and
grew into fertile adults [82]. Progress and prospects are
reviewed by Komeya and Ogawa [83]. However, this
technique is far from being applied in the human for
alleviating extreme male factor infertility. Besides the
many unresolved biological aspects, safety concerns as
well as ethical concerns require careful investigation.
Table 1 Overview of procedures for processing and selection of surgically retrieved sperm
Clinical procedure Laboratory procedure Specific sperm selection procedure
Obstructive azoospermia MESA/PESA double washing or
density gradient centrifugation
TESA/FNA immediate use
TESE mechanical processing + washing
Non-obstructive azoospermia micro-TESE mechanical processing +
immediate use immotile sperm selection if needed
TESE mechanical processing + washing (or) immotile sperm selection if needed
mechanical processing + washing + ELB (or) immotile sperm selection if needed
mechanical processing + enzymatic processing
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Conclusions
The use of ICSI with surgically retrieved sperm has
moved frontiers in the fertility treatment of the azoo-
spermic man. The sperm retrieval technique itself seems
to have no impact on the success rates of ICSI. However,
patients with NOA have lower sperm recovery rates and
lower delivery rates than OA patients. The choice of the
sperm recovery method from surgical samples and the
method to select the individual sperm for ICSI depends
on the embryologist and the laboratory equipment.
Although several techniques are available to maximize
sperm recovery and to select viable among immotile tes-
ticular sperm, only one in seven unselected NOA men
has the chance to father a biological child. The struggle
for improving the treatment outcome in NOA patients
continues. Current research is focused on in vitro
meiosis of testicular germ cells or spermatogonial stem
cells, and on in vitro spermatogenesis, starting from in-
duced pluripotent stem cells or somatic cells. However,
many biological aspects remain unresolved, and safety
and ethical concerns need careful investigation before its
clinical application.
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